Matthew Baggott's guest appearances

Matthew Baggott

Adventures Through The Mind

MAPS Podcast

Aubrey Marcus

Rachel Harris

Michael Pollan

Duncan Trussell

Rick Doblin

Shane Mauss

Andrew Weil

Carl Hart

Dan Engle

Roland Griffiths

Johns Hopkins

Mac McClelland

Ben Sessa

Robin Carhart-Harris

Cole Marta

OwlTail

This episode features Matthew Baggott of Tactogen Inc. and will explore entactogens, which are drugs like MDMA, 2C-B, and Methalone. We start with setting a basic framework for what an entactogen is and a few example drugs, before exploring the complexities in their various effects, mechanisms of action, and both the legislative and technical process of the development of novel or new entactogenic drugs. ... For links to Baggott's work, full show notes, and a link to watch this episode in video, head to bit.ly/ATTMind177  FULL TOPICS BREAKDOWN BELOW*   SUPPORT THE PODCAST  Patreon: https://patreon.com/jameswjesso Paypal Donation: https://www.paypal.com/biz/fund?id=383635S3BKJVS Merchandise:  https://www.jameswjesso.com/shop/ More Options: https://www.jameswjesso.com/support Newsletter:  https://www.jameswjesso.com/newsletter Telgram Channel:  https://t.me/jameswjesso  * Extra BIG thanks to my patrons on Patreon for helping keep this podcast alive! Especially my $23+ patrons, Andreas D, Ian C, Yvette FC, Alex F, Eliz C, Nick M, Joe A, Nanci BF, &amp; Heartwood Mushrooms ——    Episode Breakdown  (0:00) Opening (2:44) Guest Bio (4:06) Patreon thanks | Support The Show (5:42) Interview begins (6:31) What is an entactogen and what does it do? | The difference between entactogens and psychedelics (8:37) A short discussion about 2C-B (11:47) A list of different entactogens (15:30) r-MDMA vs s-MDMA (19:48) Methalone, aka bk-MDMA (21:52) 3-MMC and 4-MMC: patents, development, and legality (23:13) Why Schedule 1 makes drug development difficult (25:02) The qualities they are trying to design OUT of new entactogen drugs (pt1) (26:31) “The loss of magic” with MDMA (33:11) Serotin transporters and MDMA neuro-oxidization (36:27) Using NAC to bring back the MDMA magic | enhanced plasticity, antioxidants, and homeostasis (44:13) The qualities they are trying to design OUT of new entactogen drugs (pt2) (48:52) Why we need “take home” entactogenic drugs (53:20) Can a drug still be medicine if it’s fun, too? (58:13) The process of justifying off-label MDMA prescriptions (1:03:01) Will there be a moral backlash against the development of “good feel” drugs? (1:11:10) The negative social consequences of prohibitionist law enforcement (1:15:58) We can’t just give people psychedelics and expect society will get better (1:18:46) Problematic moves in the psychedelic biotech industry (1:25:01) Psychedelic Patent Trolling (1:32:15) How Tactogen is trying to give back to psychedelic users (1:44:16) Increasing access to health care, not just to psychedelic substances (1:49:40) Follow-up link and contact details (1:51:25) closing 

This episode features Matthew Baggott of Tactogen Inc. and will explore entactogens, which are drugs like MDMA, 2C-B, and Methalone. We start with setting a basic framework for what an entactogen is and a few example drugs, before exploring the complexities in their various effects, mechanisms of action, and both the legislative and technical process of the development of novel or new entactogenic drugs. ... For links to Baggott's work, full show notes, and a link to watch this episode in video, head to <a href="https://bit.ly/ATTMind177" rel="noopener nofollow" target="_blank">bit.ly/ATTMind177</a> FULL TOPICS BREAKDOWN BELOW* SUPPORT THE PODCAST <ul> <li>Patreon: <a href="https://patreon.com/jameswjesso" rel="nofollow" target="_blank">https://patreon.com/jameswjesso</a></li> <li>Paypal Donation: <a href="https://www.paypal.com/biz/fund?id=383635S3BKJVS" rel="nofollow" target="_blank">https://www.paypal.com/biz/fund?id=383635S3BKJVS</a></li> <li>Merchandise:  <a href="http://https//www.jameswjesso.com/shop/" rel="nofollow" target="_blank">https://www.jameswjesso.com/shop/</a></li> <li>More Options: <a href="https://www.jameswjesso.com/support" rel="nofollow" target="_blank">https://www.jameswjesso.com/support</a></li> <li>Newsletter:  <a href="http://https//www.jameswjesso.com/newsletter" rel="nofollow" target="_blank">https://www.jameswjesso.com/newsletter</a></li> <li>Telgram Channel:  <a href="https://t.me/jameswjesso" rel="nofollow" target="_blank">https://t.me/jameswjesso</a></li> </ul> * Extra BIG thanks to my patrons on Patreon for helping keep this podcast alive! Especially my $23+ patrons, Andreas D, Ian C, Yvette FC, Alex F, Eliz C, Nick M, Joe A, Nanci BF, &amp; Heartwood Mushrooms ——  Episode Breakdown <ul> <li>(0:00) Opening</li> <li>(2:44) Guest Bio</li> <li>(4:06) Patreon thanks | Support The Show</li> <li>(5:42) Interview begins</li> <li>(6:31) What is an entactogen and what does it do? | The difference between entactogens and psychedelics</li> <li>(8:37) A short discussion about 2C-B</li> <li>(11:47) A list of different entactogens</li> <li>(15:30) r-MDMA vs s-MDMA</li> <li>(19:48) Methalone, aka bk-MDMA</li> <li>(21:52) 3-MMC and 4-MMC: patents, development, and legality</li> <li>(23:13) Why Schedule 1 makes drug development difficult</li> <li>(25:02) The qualities they are trying to design OUT of new entactogen drugs (pt1)</li> <li>(26:31) “The loss of magic” with MDMA</li> <li>(33:11) Serotin transporters and MDMA neuro-oxidization</li> <li>(36:27) Using NAC to bring back the MDMA magic | enhanced plasticity, antioxidants, and homeostasis</li> <li>(44:13) The qualities they are trying to design OUT of new entactogen drugs (pt2)</li> <li>(48:52) Why we need “take home” entactogenic drugs</li> <li>(53:20) Can a drug still be medicine if it’s fun, too?</li> <li>(58:13) The process of justifying off-label MDMA prescriptions</li> <li>(1:03:01) Will there be a moral backlash against the development of “good feel” drugs?</li> <li>(1:11:10) The negative social consequences of prohibitionist law enforcement</li> <li>(1:15:58) We can’t just give people psychedelics and expect society will get better</li> <li>(1:18:46) Problematic moves in the psychedelic biotech industry</li> <li>(1:25:01) Psychedelic Patent Trolling</li> <li>(1:32:15) How Tactogen is trying to give back to psychedelic users</li> <li>(1:44:16) Increasing access to health care, not just to psychedelic substances</li> <li>(1:49:40) Follow-up link and contact details</li> <li>(1:51:25) closing</li> </ul>

Entactogens, MDMA, and Bringing New Love Drugs To Market | Matthew Baggott ~ ATTMind 177

Episode 33 of the MAPS Podcast digs deep into the archives, all the way back to Psychedelic Science 2013! Matthew Baggott discussed research on how MDMA and related drugs alter emotions and social functioning in people. Because the Phase 3 clinical trials moving full speed ahead it seemed appropriate to re-visit some of the core subject matter behind MDMA and why this research is so important. Matthew Baggott, PhD, is a neuroscientist who has been studying the perceptual and emotional effects of drugs like MDMA in healthy human volunteers for over 13 years. He was part of the first team to receive federal funding to administer MDMA to healthy people and he co-authored the first successful application to administer MDMA to people with posttraumatic stress disorder (PTSD). He earned his PhD in neuroscience from the University of California, Berkeley and is currently a postdoctoral fellow at University of Chicago.

Episode 33 of the MAPS Podcast digs deep into the archives, all the way back to Psychedelic Science 2013! Matthew Baggott discussed research on how MDMA and related drugs alter emotions and social functioning in people. Because the Phase 3 clinical trials moving full speed ahead it seemed appropriate to re-visit some of the core subject matter behind MDMA and why this research is so important. Matthew Baggott, PhD, is a neuroscientist who has been studying the perceptual and emotional effects of drugs like MDMA in healthy human volunteers for over 13 years. He was part of the first team to receive federal funding to administer MDMA to healthy people and he co-authored the first successful application to administer MDMA to people with posttraumatic stress disorder (PTSD). He earned his PhD in neuroscience from the University of California, Berkeley and is currently a postdoctoral fellow at University of Chicago.

Episode 33: Matthew Baggott - Beyond Fear - MDMA and Emotion